English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) randomized over 35 000 men into four groups: high-dose vitamin E (400 IU day−1), high-dose selenium (200 mcg day−1), combination of vitamin E and selenium, or placebo.1 The brief time period to reach full recruitment was unprecedented; thus, it seemed that participants and health-care professionals were equally eager to test the hypothesis that high-dose antioxidant supplementation could prevent prostate cancer. However, the trial was terminated early, after a median of 5.5 years due to a lack of efficacy, although at the time a non-significant (P=0.06) increased risk of prostate cancer in the vitamin E arm, and type 2 diabetes in the selenium group (P=0.16) were observed.

Heart healthy=prostate healthy: SELECT, the symbolic end of preventing prostate cancer via heart unhealthy and over anti-oxidation mechanisms?